Erasca Inc (ERAS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-12. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 36/100 (MEDIUM), 9.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 17.0% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Sector Update: Healthcare Stocks Mixed Friday Afternoon
- Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
- Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
- Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
- FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage
- Erasca Reports Second Quarter 2026 Business Updates and Financial Results
- Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0. — J Immunother Cancer 2026 Sep 21 PMID 42767771
- The absorption, distribution, metabolism, excretion, and pharmacokinetic properties of the pan-rapidly accelerated fibrosarcoma (RAF) inhibitor naporafenib in healthy subjects: An absolute bioavailability and mass balance study. — Drug Metab Dispos 2026 Aug 14 PMID 42759207
- Automated imaging response evaluation system: Prototype software tool for standardized radiographic response assessment in glioblastoma clinical trials. — Neurooncol Pract 2026 Oct PMID 42750922
- Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. — Lancet Oncol 2026 Sep PMID 42636833
- Exploring the landscape of targetable alterations in patients with glioblastoma. — Nat Rev Clin Oncol 2026 Aug 19 PMID 42618642
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Erasca Inc.
Full ERAS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.